Brokers Issue Forecasts for Genprex, Inc.’s FY2023 Earnings (NASDAQ:GNPX)
Genprex, Inc. (NASDAQ:GNPX – Free Report) – HC Wainwright issued their FY2023 earnings per share estimates for shares of Genprex in a report issued on Monday, March 25th. HC Wainwright analyst Y. Chen anticipates that the company will post earnings per share of ($24.10) for the year. HC Wainwright has a “Buy” rating and a $10.00 price objective on the stock. The consensus estimate for Genprex’s current full-year earnings is ($19.60) per share. HC Wainwright also issued estimates for Genprex’s Q4 2023 earnings at ($5.39) EPS, Q1 2024 earnings at ($3.37) EPS, Q2 2024 earnings at ($1.60) EPS, Q3 2024 earnings at ($1.18) EPS, Q4 2024 earnings at ($1.03) EPS and FY2024 earnings at ($5.85) EPS.
Genprex Stock Down 8.7 %
GNPX opened at $2.74 on Wednesday. The stock’s fifty day moving average is $5.43 and its two-hundred day moving average is $9.36. The company has a market capitalization of $4.08 million, a P/E ratio of -0.11 and a beta of -0.57. Genprex has a 52 week low of $2.70 and a 52 week high of $46.00.
Institutional Trading of Genprex
Several hedge funds and other institutional investors have recently bought and sold shares of GNPX. Jane Street Group LLC bought a new stake in Genprex during the 3rd quarter valued at $28,000. Tower Research Capital LLC TRC boosted its position in Genprex by 1,073.7% during the 3rd quarter. Tower Research Capital LLC TRC now owns 20,986 shares of the company’s stock valued at $30,000 after acquiring an additional 19,198 shares in the last quarter. XTX Topco Ltd bought a new stake in Genprex during the 2nd quarter valued at $38,000. Virtu Financial LLC boosted its position in Genprex by 43.9% during the 2nd quarter. Virtu Financial LLC now owns 29,710 shares of the company’s stock valued at $41,000 after acquiring an additional 9,069 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. bought a new stake in Genprex during the 1st quarter valued at $68,000. Institutional investors own 14.05% of the company’s stock.
Genprex Company Profile
Genprex, Inc, a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its lead product candidate is REQORSA (GPX-001) that is in Phase 1/2 and 2 clinical trials to treat non-small cell lung cancer and small cell lung cancer. The company is also developing GPX-002 for the treatment of type 1 diabetes, and GPX-003 for the treatment of type 2 diabetes.
Read More
Receive News & Ratings for Genprex Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Genprex and related companies with MarketBeat.com’s FREE daily email newsletter.
